PubMed

Int J Food Microbiol. 2022 Dec 9;387:110056. doi: 10.1016/j.ijfoodmicro.2022.110056. Online ahead of print.ABSTRACTLamb meat is an important export commodity, however chilled vacuum-packed (VP) lamb has approximately half the shelf-life of beef under the same storage conditions. This makes the industry more vulnerable to financial losses due to long shipping times and unexpected spoilage. Understanding the spoilage mechanisms of chilled VP lamb in relation to VP beef is important for developing effective strategies to extend the shelf-life of lamb. This review has discussed various key factors (i.e., pH, fat, and presence of bone) that have effects on microbial spoilage of VP lamb contributing to its shorter shelf-life relative to VP beef. A range of bacterial organisms and their metabolisms in relevance to lamb spoilage are also discussed. The data gap in the literature regarding the potential mechanisms of spoilage in VP red meat is highlighted. This review has provided the current understanding of key factors affecting the shelf-life of VP lamb relative to VP beef. It has also identified key areas of research to further understand the spoilage mechanisms of VP lamb. These include investigating the potential influence of fat and bone (including bone marrow) on the shelf-life, as well as assessing changes in the meat metabolome as the spoilage microbial community is developing using an integrated approach. Such new knowledge would aid the development of effective approaches to extend the shelf-life of VP lamb.PMID:36563532 | DOI:10.1016/j.ijfoodmicro.2022.110056

Int J Hyg Environ Health. 2022 Dec 21;248:114105. doi: 10.1016/j.ijheh.2022.114105. Online ahead of print.ABSTRACTHumans are exposed to a mixture of pesticides through diet as well as through the environment. We conducted a suspect-screening based study to describe the probability of (concomitant) exposure to a set of pesticide profiles in five European countries (Latvia, Hungary, Czech Republic, Spain and the Netherlands). We explored whether living in an agricultural area (compared to living in a peri-urban area), being a a child (compared to being an adult), and the season in which the urine sample was collected had an impact on the probability of detection of pesticides (-metabolites). In total 2088 urine samples were collected from 1050 participants (525 parent-child pairs) and analyzed through harmonized suspect screening by five different laboratories. Fourty pesticide biomarkers (either pesticide metabolites or the parent pesticides as such) relating to 29 pesticides were identified at high levels of confidence in samples across all study sites. Most frequently detected were biomarkers related to the parent pesticides acetamiprid and chlorpropham. Other biomarkers with high detection rates in at least four countries related to the parent pesticides boscalid, fludioxonil, pirimiphos-methyl, pyrimethanil, clothianidin, fluazifop and propamocarb. In 84% of the samples at least two different pesticides were detected. The median number of detected pesticides in the urine samples was 3, and the maximum was 13 pesticides detected in a single sample. The most frequently co-occurring substances were acetamiprid with chlorpropham (in 62 urine samples), and acetamiprid with tebuconazole (30 samples). Some variation in the probability of detection of pesticides (-metabolites) was observed with living in an agricultural area or season of urine sampling, though no consistent patterns were observed. We did observe differences in the probability of detection of a pesticide (metabolite) among children compared to adults, suggesting a different exposure and/or elimination patterns between adults and children. This survey demonstrates the feasibility of conducting a harmonized pan-European sample collection, combined with suspect screening to provide insight in the presence of exposure to pesticide mixtures in the European population, including agricultural areas. Future improvements could come from improved (harmonized) quantification of pesticide levels.PMID:36563507 | DOI:10.1016/j.ijheh.2022.114105

Gut Microbes. 2023 Jan-Dec;15(1):2156255. doi: 10.1080/19490976.2022.2156255.ABSTRACTIntrahepatic cholangiocarcinoma (ICC) is a rare malignancy with a high prevalence in China. This study aimed to characterize the ICC tissues' bacterial metagenomics signature and explore its antitumor potential for cancer. In this study, 16S rRNA sequencing was carried out on 99 tissues to characterize the features of intratumoral microbiota, followed by single-cell RNA sequencing (scRNA-seq) and multilevel validation. The presence of microbial DNA in tissues was determined using staining, fluorescence in situ hybridization (FISH), and transmission electron microscopy (TEM). A Gram-positive aerobic bacterium, identified as Staphylococcus capitis, was cultured from fresh tissues. Meanwhile, scRNA-seq showed that intratumoral bacteria could be present in multiple cell types. Using 16S rRNA sequencing, we identified a total of 2,320,287 high-quality reads corresponding to 4,594 OTU (operational taxonomic units) sequences. The most abundant bacterial orders include Burkholderiales, Pseudomonadales, Xanthomonadales, Bacillales and Clostridiales. Alpha and Beta diversity analysis revealed specific features in different tissues. In addition, the content of Paraburkholderia fungorum was significantly higher in the paracancerous tissues and negatively correlated with CA199 (Carbohydrate antigen199) levels. The results of in vitro and in vivo experiments suggest that P. fungorum possesses an antitumor activity against tumors. Metabolomics and transcriptomics showed that P. fungorum could inhibit tumor growth through alanine, aspartate and glutamate metabolism. We determined the characteristic profile of the intratumoral microbiota and the antitumor effect of P. fungorum in ICC.PMID:36563106 | DOI:10.1080/19490976.2022.2156255

Food Funct. 2022 Dec 23. doi: 10.1039/d2fo02842e. Online ahead of print.NO ABSTRACTPMID:36562313 | DOI:10.1039/d2fo02842e

Pharm Biol. 2023 Dec;61(1):111-124. doi: 10.1080/13880209.2022.2157020.NO ABSTRACTPMID:36562308 | DOI:10.1080/13880209.2022.2157020

Gynecol Endocrinol. 2022 Dec 23:1-6. doi: 10.1080/09513590.2022.2160869. Online ahead of print.NO ABSTRACTPMID:36562249 | DOI:10.1080/09513590.2022.2160869

J Pineal Res. 2022 Dec 22. doi: 10.1111/jpi.12849. Online ahead of print.NO ABSTRACTPMID:36562106 | DOI:10.1111/jpi.12849

Front Cardiovasc Med. 2022 Dec 6;9:1047322. doi: 10.3389/fcvm.2022.1047322. eCollection 2022.NO ABSTRACTPMID:36561767 | PMC:PMC9763324 | DOI:10.3389/fcvm.2022.1047322

Heliyon. 2022 Dec 8;8(12):e12126. doi: 10.1016/j.heliyon.2022.e12126. eCollection 2022 Dec.NO ABSTRACTPMID:36561668 | PMC:PMC9764190 | DOI:10.1016/j.heliyon.2022.e12126

Front Plant Sci. 2022 Dec 6;13:1062982. doi: 10.3389/fpls.2022.1062982. eCollection 2022.NO ABSTRACTPMID:36561464 | PMC:PMC9763704 | DOI:10.3389/fpls.2022.1062982

Front Plant Sci. 2022 Dec 6;13:1023764. doi: 10.3389/fpls.2022.1023764. eCollection 2022.NO ABSTRACTPMID:36561440 | PMC:PMC9763449 | DOI:10.3389/fpls.2022.1023764

Front Microbiol. 2022 Dec 6;13:1071530. doi: 10.3389/fmicb.2022.1071530. eCollection 2022.NO ABSTRACTPMID:36560956 | PMC:PMC9763614 | DOI:10.3389/fmicb.2022.1071530

Front Microbiol. 2022 Dec 6;13:988984. doi: 10.3389/fmicb.2022.988984. eCollection 2022.NO ABSTRACTPMID:36560955 | PMC:PMC9763702 | DOI:10.3389/fmicb.2022.988984

Mol Ther. 2022 Dec 21:S1525-0016(22)00715-8. doi: 10.1016/j.ymthe.2022.12.011. Online ahead of print.NO ABSTRACTPMID:36560881 | DOI:10.1016/j.ymthe.2022.12.011

Vaccines (Basel). 2022 Dec 12;10(12):2127. doi: 10.3390/vaccines10122127.NO ABSTRACTPMID:36560537 | DOI:10.3390/vaccines10122127

Plants (Basel). 2022 Dec 17;11(24):3574. doi: 10.3390/plants11243574.NO ABSTRACTPMID:36559686 | DOI:10.3390/plants11243574

Plants (Basel). 2022 Dec 9;11(24):3457. doi: 10.3390/plants11243457.NO ABSTRACTPMID:36559570 | DOI:10.3390/plants11243457

Pharmaceutics. 2022 Dec 14;14(12):2803. doi: 10.3390/pharmaceutics14122803.NO ABSTRACTPMID:36559296 | DOI:10.3390/pharmaceutics14122803

Pharmaceutics. 2022 Dec 8;14(12):2751. doi: 10.3390/pharmaceutics14122751.NO ABSTRACTPMID:36559245 | DOI:10.3390/pharmaceutics14122751

Pharmaceuticals (Basel). 2022 Nov 29;15(12):1484. doi: 10.3390/ph15121484.NO ABSTRACTPMID:36558935 | DOI:10.3390/ph15121484